Table 4:

Ongoing Clinical Trials in Newly Diagnosed Multiple Myeloma with MRD as the Primary Endpoint.

NCT Number	Title	Acronym	Status	Enrollment	Funded By	Estimated Primary Completion Date	Comments
NCT03652064	A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy	CEPH EUS	Active, not recruiting	395	Industry	Oct-20	Primary endpoint: MRD
NCT03901963	A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant	AURI GA	Recruiting	214	Industry	May-21	Primary endpoint : MRD
NCT04268498	A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma	ADVA NCE	Recruiting	462	Other	Feb-22	Primary endpoint: MRD
NCT04096066	A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant (KRd vs Rd)	EMN20	Recruiting	340	Other	Jul-24	Co-primary MRD and PFS
NCT03617731	Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomi b/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma	GMMG HD7	Recruiting	662	Other	May-25	Two-stage randomization. Endpoint for induction therapy: MRD
NCT04091126	Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma	DREA MM-9	Recruiting	810	Industry	Jun-25	Two-part study. Phase 3 part: Co-primary MRD and PFS endpoint